

Table SI. Overview of cases with immune-related lichen planus (LP)

Ref.	Tumour disease	Sex/ age ^a , years	PD-1/PD-L1	Indication	Time ^a until manifestation of LP (weeks)	Subtype of LP	Staging at time of diagnosis of LP	Treatment of LP	Immuno-therapy	Outcome of LP	Outcome of tumour disease
S1	Melanoma	M/52	PD-1 (pembrolizumab)	Metastatic	12	Hypertrophic	NS	TCS + SCS	Continued	Completely resolved	NS
S2	Non-small cell lung cancer	M/78	PD-1 (pembrolizumab)	Metastatic	6	Hypertrophic	NS	doxycycline	Stopped	Completely resolved	NS
S3	Lung adenocarcinoma	F/73	PD-L1 (durvalumab)	Metastatic	Not specified	Hypertrophic	NS	TCS	Stopped	Partially Resolved	NS
S4	Merkel cell carcinoma	M/73	PD-L1 (avelumab)	Metastatic	4	Hypertrophic	Complete response	TCS	Continued	Completely resolved	Complete response
S5	Non-small cell lung cancer	M/51	PD-1 (nivolumab)	Metastatic	2	Hypertrophic	Stable disease	TCS	Continued	Completely resolved	Complete response
S6	Non-small cell lung cancer	F/64	PD-1 (nivolumab)	Adjuvant	Not specified	Hypertrophic	Stable disease	TCS	Continued	Partially Resolved	Stable disease
S7	Lung adenocarcinoma	M/86	PD-1 (nivolumab)	Metastatic	Not specified	Hypertrophic	Complete response	TCS	Continued	Completely resolved	Complete response
S8	Lung adenocarcinoma	F/78	PD-1 (pembrolizumab)	Adjuvant	24	Hypertrophic	NS	TCS + SCS	Stopped	Completely resolved	NS
S9	Non-small cell lung cancer	F/87	PD-1 (nivolumab)	Metastatic	12	Bullous	Stable disease	SCS	Stopped	Completely resolved	Stable disease
S10	Renal cell carcinoma	F/25	PD-1 (nivolumab)	Metastatic	20	Bullous	Partial response	TCS	Continued	Completely resolved	Partial response
S11	Non-small cell lung cancer	F/71	PD-1 (pembrolizumab)	Metastatic	4	Bullous	Stable disease	TCS + systemic retinoids	Continued	Completely resolved	Stable disease
	Melanoma	F/49	PD-1 (pembrolizumab)	Metastatic	6	Bullous	Progress	SCS + systemic retinoids	Stopped	Completely resolved	Progress
	Non-small cell lung cancer	M/86	PD-1 (pembrolizumab)	Metastatic	66	Bullous	Stable disease	TCS	Stopped	Completely resolved	Stable disease
S12	Non-small cell lung cancer	F/71	PD-1 (pembrolizumab)	Metastatic	4	Bullous	Stable disease	TCS + systemic retinoids	Continued	Completely resolved	Stable disease
S13	Melanoma	M/64	PD-1 (pembrolizumab)	Metastatic	51	Bullous	Complete response	TCS + SCS + Rituximab	Stopped	Completely resolved	Complete response
S14	Urotheliale Carcinoma	M/76	PD-1 (pembrolizumab)	Metastatic	12	Bullous	Progress	TCS + SCS	Stopped	Completely resolved	Progress
S15	Melanoma	F/NS	PD-1 (pembrolizumab)	Metastatic	6	Not Specified	Progress	TCS	Stopped	Partially resolved	Progress
S16	Melanoma	M/46	PD-1 (pembrolizumab)	Metastatic	24	Not Specified	Progress	TCS + SCS	Continued	Completely resolved	Progress
S17	Lung adenocarcinoma	F/60	PD-1 (nivolumab)	Metastatic	20	Not Specified	Stable disease	TCS + SCS	Stopped	Partially resolved	Stable disease
	Melanoma	M/77	PD-1 (pembrolizumab)	Adjuvant	24	Ulcerated	Stable disease	TCS + SCS	Continued	Partially resolved	Stable disease

^aMean age 66.6 years. ^bMean time 17 weeks

TCS: topical corticosteroids; SCS: systemic corticosteroids; NS: not specified.

SUPPLEMENTARY REFERENCES

- S1. Kim G, Synkowski D, Daniels G, Hinds B. Hypertrophic lichen planus-like eruption secondary to pembrolizumab for metastatic melanoma. *J Am Acad Dermatol* 2018; 79: AB155.
- S2. Fontecilla NM, Kittler NW, Lopez A, Yang C, Geskin L. Programmed cell death protein-1 inhibitor-induced granuloma annulare and hypertrophic lichen planus masquerading as squamous cell carcinoma. *J Am Acad Dermatol Case Rep* 2018; 4: 636-639.
- S3. Myrdal CN, Sundararajan S, Curiel-Lewandrowski C. Widespread hypertrophic lichen planus following programmed cell death ligand 1 blockade. *Case Rep Dermatol* 2020; 12: 119-123.
- S4. Cardis MA, Jiang H, Strauss J, Gullely JL, Brownell I. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report. *BMC Cancer* 2019; 19: 539.
- S5. Maarouf M, Alexander C, Shi VY. Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature. *Dermatol Online J* 2018; 24: 13030/qt4xf465w6.
- S6. Veasey EN, Callen JP, Haerberle T. Hypertrophic lichen planus secondary to nivolumab therapy. *J Am Acad Dermatol* 2018; 79: AB154.
- S7. Lee AK, Little AJ, Zubek AE. Nivolumab-induced hypertrophic lichen planus and eruptive keratoacanthomas. *J Am Acad Dermatol* 2019; 81: AB97.
- S8. Coscarart A, Martel J, Lee MP, Wang AR. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus. *J Cutan Pathol* 2020; 47: 275-279.
- S9. Strickley JD, Vence LM, Burton SK, Callen JP. Nivolumab-induced lichen planus pemphigoides. *Cutis* 2019; 103: 224-226.
- S10. Yilmaz M, Mese SG, Celik U. Nivolumab-induced lichen planus. *J Oncol Pharm Pract* 2020; 26: 758-760.
- S11. Wakade DV, Carlos G, Hwang SJ, Chou S, Hui R, Fernandez-Penas P. PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. *Melanoma Res* 2016; 26: 421-424.
- S12. Carlos G, Anforth R, Chou S, Hui R, Fernandez-Penas P. Bullous annular lichen planus in a patient on Pembrolizumab. *Australas J Dermatol* 2015; 56: 23-24.
- S13. Schmidgen MI, Butsch F, Schadmand-Fischer S, Steinbrink K, Grabbe S, Weidenthaler-Barth B et al. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma. *J Dtsch Dermatol Ges* 2017; 15: 742-745.
- S14. Okada H, Kamiya K, Murata S, Sugihara T, Sato A, Maekawa T et al. Case of lichen planus pemphigoides after pembrolizumab therapy for advanced urothelial carcinoma. *J Dermatol* 2020; 47: e321-e322.
- S15. Kratzsch D, Simon JC, Ziemer M. Lichen planus-like drug eruption on anti-PD-1 therapy. *J Dtsch Dermatol Ges* 2017; 15: 1238-1240.
- S16. Denny J, Chong H, Akhras V. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma. *Clin Exp Dermatol* 2018; 43: 354-356.
- S17. Lee M, Seetharamu N. An atypical presentation of lichen planus-like reaction from pembrolizumab. *Case Rep Dermatol Med* 2019; 2019: 4065437.